
Duane A Mitchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/502013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 4722-4729.	1.6	702
2	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	27.8	429
3	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology, 2008, 10, 10-18.	1.2	323
4	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011, 13, 324-333.	1.2	306
5	An epidermal growth factor receptor variant Ill–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics, 2009, 8, 2773-2779.	4.1	262
6	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	7.0	215
7	Infiltrative and drugâ€resistant slowâ€cycling cells support metabolic heterogeneity in glioblastoma. EMBO Journal, 2018, 37, .	7.8	118
8	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood, 2011, 118, 3003-3012.	1.4	104
9	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research, 2016, 22, 582-595.	7.0	88
10	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.9	82
11	Recognition and Killing of Autologous, Primary Clioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research, 2014, 20, 2684-2694.	7.0	74
12	Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. International Journal of Cancer, 2017, 141, 1434-1444.	5.1	70
13	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research, 2020, 80, 499-509.	0.9	68
14	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research, 2020, 26, 5297-5303.	7.0	67
15	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research, 2013, 1, 163-167.	3.4	61
16	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. Frontiers in Immunology, 2017, 8, 1451.	4.8	47
17	Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses. Critical Reviews in Oncology/Hematology, 2016, 107, 100-110.	4.4	43
18	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncolmmunology, 2015, 4, e994374.	4.6	41

DUANE A MITCHELL

#	Article	IF	CITATIONS
19	Selective Modification of Antigen-Specific T Cells by RNA Electroporation. Human Gene Therapy, 2008, 19, 511-521.	2.7	39
20	Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors. Neurotherapeutics, 2009, 6, 527-538.	4.4	37
21	Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. Clinical Cancer Research, 2018, 24, 3955-3966.	7.0	34
22	Linâ^'CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. Nature Communications, 2018, 9, 4313.	12.8	32
23	Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. Clinical Cancer Research, 2020, 26, 5689-5700.	7.0	26
24	Vaccination strategies for neuro-oncology: Table 1 Neuro-Oncology, 2015, 17, vii15-vii25.	1.2	25
25	Adoptive Immunotherapy for Malignant Glioma. Cancer Journal (Sudbury, Mass), 2003, 9, 157-166.	2.0	21
26	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
27	Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances, 2019, 5, eaav9879.	10.3	17
28	Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. Stem Cells, 2019, 37, 166-175.	3.2	17
29	Temozolomide as a vaccine adjuvant in GBM. Journal of Clinical Oncology, 2007, 25, 2020-2020.	1.6	14
30	Reply to M.S. Lesniak. Journal of Clinical Oncology, 2011, 29, 3105-3106.	1.6	9
31	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 161-176.	2.9	6
32	Effects of immune checkpoint blockade on antigenâ€specific CD8 ⁺ T cells for use in adoptive cellular therapy. Microbiology and Immunology, 2022, 66, 201-211.	1.4	6
33	Is There a Role for Immunotherapy in Central Nervous System Cancers?. Hematology/Oncology Clinics of North America, 2022, 36, 237-252.	2.2	5
34	Adoptive cell therapy for glioma. , 2022, , 73-89.		1